Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferrous Maltol Capsules for Iron Deficiency Anemia in Quiescent Inflammatory Bowel Disease
ChiCTR2600130008Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ferric maltol in iron deficiency anemia (IDA), inflammatory bowel disease (IBD), autoimmune colitis and 1 more (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Change from baseline in hemoglobin at 12 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on ChiCTR2600130008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130008.